Partial progress: governing the pharmaceutical industry and the NHS, 1948-2008

Area of Science:

• Health policy
• Pharmaceutical governance
• Sociology of medicine

Background:

• Review of the UK National Health Service (NHS) at its 60th anniversary.
• Exploration of the complex relationship between the pharmaceutical industry, the state, and the NHS.
• Examination of challenges including drug safety, efficacy, cost-effectiveness, pricing, promotion, and advertising.

Observation:

• Analysis draws on concepts like "corporate bias," "regulatory capture," "counter-vailing powers," and "clinical autonomy."
• Introduction of new concepts: "assimilated allies" and "pharmaceuticalization."
• Synthesis of a theoretical framework for analyzing pharmaceutical governance over time.

Findings:

• Identifies progress in healthcare attributed to pharmaceutical and NHS governance since 1948.
• Argues progress has been slow, restricted, and prone to misdirection.
• Highlights the significant and often unchecked influence of the pharmaceutical industry on policy.

Implications:

• Suggests that countervailing powers against corporate bias have been limited.
• Notes the destabilizing effect of industry "assimilated allies" within the state.
• Discusses the impact of "pharmaceuticalization" and consumerism on governance dynamics.